drugset / Trial / NCT00958152

Drug-Drug Interaction Study of VCH-222 and Telaprevir in Healthy Subjects

NCT00958152

Phase 1 Completed 30 enrolled Vertex Pharmaceuticals Incorporated
RandomizedParallel-groupQuadruple-blind

Summary

The purpose of this study is to investigate the pharmacokinetics, safety, and tolerability of the co-administration of VCH-222 and telaprevir in healthy subjects.

Timeline

Start
2009-08
Primary completion
2010-01
Completion
2010-01

Drugs

EvaluationDrugModalityDoseRoute
Subject LOMIBUVIR Small molecule 400 mg Oral
Subject LOMIBUVIR Small molecule 750 mg Oral
Subject LOMIBUVIR Small molecule 1000 mg Oral
Subject Telaprevir Small molecule 1125 mg Oral